Skip to main content
SpringerLink
Log in

Comparison of Wilms’ tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Clinical studies have shown that NST has better therapeutic results with chronic myelogenous leukemia (CML) than acute leukemia (AL), but whether the generation of graft-versus-leukemia (GVL) effects is different between AL and CML patients early after NST has not yet been studied, so we used a pentamer-staining technique in combination with ICCS to detect WT1+CD8+CTL/WT1+Tc1 and WT1+Th1 cells in these two groups of patients. Results showed that the emergence time of WT1+CD8 +CTL/WT1+Tc1 cells after NST in AL patients was similar to that in CML patients (P = 0.58), while the emergence time of WT1+Th1 cells after NST in AL patients was shorter than in CML patients (P = 0.047). Furthermore, the peak proportions of WT1+CD8 +CTL/WT1+Tc1 (P > 0.05) and WT1+Th1 (P > 0.05) cells were similar between AL and CML patients, and the increased rates (P > 0.05) and elevated levels (P > 0.05) of WT1-specific T cells were not statistically different between the groups after G-CSF mobilized donor mononuclear cell infusion. In addition, the reconstruction of lymphocyte subsets (P > 0.05) and CD4/8 ratios (P > 0.05) in AL patients were not statistically different from those in CML patients within 180 days after NST. These results suggested that WT1 maybe induces similar GVL effects in both AL and CML patients early after NST.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(1):555–62.

    CAS  PubMed  Google Scholar 

  2. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73.

    CAS  PubMed  Google Scholar 

  3. Van Rhee F, Kolb H-J. Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol. 1995;2:423–9.

    Article  PubMed  Google Scholar 

  4. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–50.

    CAS  PubMed  Google Scholar 

  5. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110(6):1924–32.

    Article  CAS  PubMed  Google Scholar 

  6. Michallet AS, Nicolini F, Fürst S, et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant. 2005;35(6):601–8.

    Article  CAS  PubMed  Google Scholar 

  7. Liubimova LS, Savchenko VG, Mendeleeva LP, et al. Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase. Ter Arkh. 1999;71(7):27–32.

    CAS  PubMed  Google Scholar 

  8. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft-versus-leukemia effect. Br J Haematol. 1988;69:239–45.

    Article  CAS  PubMed  Google Scholar 

  9. Huang XJ, Liu DH, Liu KY, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92(3):414–7.

    Article  PubMed  Google Scholar 

  10. Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant. 1996;2(3):118–25.

    CAS  PubMed  Google Scholar 

  11. Sun WJ, Guo ZK, Ai HS. The antitumor activity of G-CSF-mobilized peripheral blood mononuclear cells activated by IL-2 alone or in combination with IL-12. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005;13:687–91.

    PubMed  Google Scholar 

  12. Hui-Sheng A, Chun-Hua Zhao R, Guo M, et al. Mixed hematopoietic chimerism—a new strategy for preventing GVHD in nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2002;30:119.

    Google Scholar 

  13. Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res. 2006;12:7476–82.

    Article  CAS  PubMed  Google Scholar 

  14. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, et al. T-Cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms’ Tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11:8799–807.

    Article  CAS  PubMed  Google Scholar 

  15. Chen MH, Chiou TJ, Lin PC, et al. Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol. 2007;86(3):275–81.

    Article  CAS  PubMed  Google Scholar 

  16. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36):9387–93.

    Article  CAS  PubMed  Google Scholar 

  17. Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia. 2004;18(11):1789–97.

    Article  CAS  PubMed  Google Scholar 

  18. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742–7.

    Article  CAS  PubMed  Google Scholar 

  19. Shaw BE, Byrne JL, Das-Gupta E, Carter GI, Russell NH. The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. Biol Blood Marrow Transplant. 2007;13(5):550–9.

    Article  PubMed  Google Scholar 

  20. Smit WM, Rijnbeck M, van Bergen CAM, et al. Dendritic cells generated from FACS sorted chronic myeloid leukemia (CML) precursor cells express BCR/ABL, and are potent stimulators for allogeneic T cells. Br J Haematol. 1996;93:313a.

    Google Scholar 

  21. Mittermueller J, Kolb HJ, Gerhartz HH, Wilmanns W. In vivo differentiation of leukemic blasts and effect of low dose ara-c in a marrow grafted patient with leukemic relapse. Br J Haematol. 1986;62:757–62.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Affiliated Hospital of Academy of Military Medicine Science, 100071, Beijing, China

    Wei Li, Zuo HongLi, Sun XueDong, Liu TieQiang, Guo Mei, Liu GuangXian, Sun QiYun, Qiao JianHui, Wang DanHong, Yu ChangLin, Hu KaiXun, Dong Zheng & Ai HuiSheng

Authors
  1. Wei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zuo HongLi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sun XueDong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liu TieQiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guo Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liu GuangXian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sun QiYun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qiao JianHui
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wang DanHong
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu ChangLin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hu KaiXun
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ai HuiSheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ai HuiSheng.

About this article

Cite this article

Li, W., HongLi, Z., XueDong, S. et al. Comparison of Wilms’ tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. Int J Hematol 91, 652–660 (2010). https://doi.org/10.1007/s12185-010-0551-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0551-7

Keywords

Search

Navigation